Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Plasma Epstein Barr Virus (EBV)-DNA is an established biomarker for endemic EBV-related nasopharyngeal carcinoma (NPC). Its relevance in non-endemic regions is less understood. This study longitudinally assessed plasma EBV-DNA (LEA study) throughout the curative management of non-endemic EBV-related NPC to evaluate its prognostic value. MATERIALS AND METHODS: Between 2012 and 2023, patients with non-endemic, non-metastatic, histologically confirmed EBER+ NPC treated at a tertiary center were retrospectively analyzed. Plasma EBV-DNA levels were measured at pre-treatment (T1), early (T2a, ≤6 weeks) and late (T2b, ≤14 weeks) post-treatment, during follow-up (T3), and after induction chemotherapy (T4), when applicable. EBV-DNA was analyzed for its association with recurrence-free survival (RFS). RESULTS: At a median follow-up of 60 months (range: 9-134), 167 patients were included. Median age was 50 years (range: 22-75), with 72 % male; 84 % had stage III-IV disease (TNM VIII Edition). Pre-treatment EBV-DNA was detected in 96 % of patients, with no predictive cut-off (median RFS: 43 vs. 62 months for detectable vs. undetectable EBV-DNA). Post-treatment undetectable EBV-DNA correlated with better RFS, also with no cut-off. Follow-up EBV-DNA anticipated recurrence in 71 % of cases by a median of 38 days (range: 11-365). Persistently negative follow-up EBV-DNA was observed in 91 % of non-recurrent patients; isolated positive spikes lacked prognostic significance. Post-induction chemotherapy EBV-DNA demonstrated a 92 % negative predictive value for recurrence. CONCLUSIONS: Plasma EBV-DNA is a valuable prognostic biomarker for non-endemic NPC. Pre- and post-treatment undetectable EBV-DNA holds a positive prognostic value. Post-induction EBV-DNA is the most informative timepoint. Longitudinal EBV-DNA monitoring is warranted in clinical practice.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study
- Date Crossref
- 01/08/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Fondazione IRCCS Istituto Nazionale dei Tumori pays non établi dans la noticeÉtablissement de santé
-
University of Milan Department of Health Sciences pays non établi dans la noticeUniversité ou école supérieure
-
National Center for Oncological Hadrontherapy pays non établi dans la noticeOrganisation à but non lucratif
-
Istituti Clinici Scientifici Maugeri pays non établi dans la noticeÉtablissement de santé
-
IRCCS Humanitas Research Hospital Department of Biomedical Sciences pays non établi dans la noticeÉtablissement de santé
-
Department of Head and Neck Medical Oncology pays non établi dans la noticeInstitution
-
Immunohematology and Transfusion Medicine Service pays non établi dans la noticeInstitution
-
Experimental Oncology pays non établi dans la noticeInstitution
-
Department of Radiation Oncology 2 pays non établi dans la noticeInstitution
-
Department of Otorhinolaryngology pays non établi dans la noticeOrganisation à but non lucratif
-
Radiation Oncology Clinical Department pays non établi dans la noticeÉtablissement de santé
-
University of Pavia Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) pays non établi dans la noticeUniversité ou école supérieure
Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Health Sciences — University of Milan et National Center for Oncological Hadrontherapy, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.